Strategic partnerships Position Wheeler Bio as a reliable CDMO with Portable CMC capabilities aiming to streamline discovery to development for antibody and antibody-like therapeutics, highlighting potential partners seeking integrated platforms from discovery through CGMP supply.

Clinical supply focus Leverage expertise in CGMP clinical material supply and GLP tox material to target mid to late-stage biotech companies requiring scalable, compliant manufacturing and timely clinical material readiness.

Recent leadership Take advantage of new executive leadership and recent hires to approach Wheeler Bio as a growing, strategically energized organization open to new collaborations, co-development models, and process optimizations.

Financing momentum Capitalize on Series A1 financing and ongoing investor interest to explore co-investment or milestone-based partnerships around expanding capacity, technology integration, and joint development programs.

Integrated platform Propose opportunities to integrate Wheeler Bio’s Portable CMC platform with partner programs via existing alliances (Charles River, Alloy Therapeutics) to accelerate lead optimization, reduce lifecycle bottlenecks, and shorten time to IND.